All In Biotech

Drug Trial Radar · NCT07010497

A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular Carcinoma

A PHASE 2, OPEN-LABEL STUDY OF IRPAGRATINIB IN COMBINATION WITH ATEZOLIZUMAB AND BEVACIZUMAB IN PATIENTS WITH ADVANCED OR UNRESECTABLE HEPATOCELLULAR CARCINOMA (IAPETUS)

Last checked: Nov 20, 2026Latest source record: Jul 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

33

Planned (sponsor's estimate)

Start

Mar 16, 2026

Primary completion

Mar 31, 2029

Study completion Mar 31, 2029

Sponsor

Lead sponsor
Asan Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Abbisko Therapeutics Co, Ltd
First posted
Jun 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 2, open-label study to evaluate the safety, tolerability and efficacy of Irpagratinib in combination with Atezolizumab and Bevacizumab in patients with advanced or unresectable HCC harboring FGF19 overexpression. This study composes two parts, a Safety Run-in part to evaluate safety and establish the dose of Irpagratinib for the triple combination, and an Expansion part to evaluate the preliminary efficacy and safety using Simon's two-stage design.

Conditions

  • Carcinoma, Hepatocellular

Interventions

  • irpagratinibDrug

    Patients will receive oral administration of ABSK-011 capsules in a repetitive dosing regimen for a period of 21 consecutive days as a cycle, either once daily or twice daily, until the investigators make a comprehensive assessment of imaging examinations, laboratory data, and the clinical condition of the patients, and determine that there is intolerable toxicity or disease progression.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of DLTsTime frame: Safety Run-in: At the end of Cycle 1 (each cycle is 21 days)
  2. Objective response rate (ORR)Time frame: through study completion, an average 21months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Asan Medical Center,

    Seoul, South Korea · Recruiting

  • Seoul National University Hospital

    Seoul, South Korea · Not yet recruiting

  • Severance Hospital

    Seoul, South Korea · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.